Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

59
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
59
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

72
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
72
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

63
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
63
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

69
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
69
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

107
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HERZCHECK: Early Detection of Subclinical Preheart Failure Using Mobile Cardiac Magnetic Resonance and Telemedicine in Rural and Underressourced Regions.

Circulation. Heart failure·2026
Same author

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Nature reviews. Drug discovery·2026
Same author

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026
Same author

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

The New England journal of medicine·2026
Same author

Methacrylated gelatin-based conductive self-healing hydrogels: a dual-scale approach for micro- and macro-sized soft materials.

RSC applied polymers·2026
Same author

Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.

ESC heart failure·2026

Related Experiment Video

Updated: Nov 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Phase I dose-escalation oncology trials with sequential multiple schedules.

Burak Kürsad Günhan1, Sebastian Weber2, Abdelkader Seroutou2

  • 1Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany. burak.gunhan@med.uni-goettingen.de.

BMC Medical Research Methodology
|April 15, 2021
PubMed
Summary

New time-to-event pharmacokinetics (TITE-PK) models improve sequential phase I oncology trials by integrating data from multiple dosing schedules. This approach enhances dose selection and avoids toxicity, performing better than existing methods with similar patient numbers.

Keywords:
Bayesian statisticsMultiple treatment schedulesPK modelsPhase I dose-escalation trials

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Related Experiment Videos

Last Updated: Nov 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacokinetics

Background:

  • Traditional phase I oncology trials use single treatment schedules.
  • Investigating multiple schedules within a single trial is becoming more common.

Purpose of the Study:

  • To adapt the time-to-event pharmacokinetics (TITE-PK) model for sequential phase I trials with multiple schedules.
  • To improve dose-level decision-making by integrating data from completed and ongoing schedules.

Main Methods:

  • Adapted the TITE-PK model for sequential trial designs.
  • Integrated pharmacokinetic (PK) modeling to combine information across multiple schedules.
  • Compared the adapted TITE-PK model against existing methods (bridging CRM, Bayesian logistic regression) via simulation.

Main Results:

  • The adapted TITE-PK model demonstrated superior performance in recommending acceptable doses and avoiding overly toxic doses in sequential phase I trials compared to other methods.
  • This improved performance was achieved with a similar number of patients required.
  • For single-schedule scenarios, TITE-PK performance was comparable to existing methods.

Conclusions:

  • The adapted TITE-PK model is recommended for phase I oncology trials employing sequential multiple schedules.
  • Utilizing all available information, including PK principles, is crucial for effective dose escalation in these complex trial designs.